Thyroid Eye Disease Treatment in China 2026: drugs, decompression, timing
In March 2025 China licensed its own IGF-1R antibody for thyroid eye disease — teprotumumab N01, the same drug class as the US product whose list price is around US$146,000 for a full course. After national price negotiation the Chinese drug is reported at roughly RMB 5,966 per vial, which puts a fifteen-vial course near RMB 89,000–95,000, on the order of US$12,400–13,200 in drug cost. Orbital decompression runs $3,500–6,500 per orbit against a published US average of about $21,875 per encounter. Those numbers are real and they are the reason this page exists. They are also not the number that should decide anything, because thyroid eye disease is the condition where timing beats price: the drug course takes five months, the surgery has to wait for the disease to burn out, and the sight-threatening version of this illness is a reason to be seen at home today rather than to book a flight.
IGF-1R antibody course (15 vials, 8 infusions) ~RMB 89,000–95,000 ≈ US$12,400–13,200 plus $900–1,800 infusion and monitoring · intravenous methylprednisolone protocol $700–1,500 · orbital radiotherapy course $1,800–3,500 · two-wall orbital decompression $3,500–6,500 per orbit · strabismus correction $1,400–3,600 · eyelid retraction repair $1,200–3,200 per lid. Three rules decide whether any of it applies to you, and none of them is money: the disease has to be inactive before rehabilitative surgery, the surgical order is decompression → strabismus → eyelids, and the eight-infusion drug course spans about twenty-one weeks, so it cannot be done as a medical trip. If your vision or colour perception is changing, stop reading and be seen where you are.
About 5 in 100 people with thyroid eye disease develop compressive optic neuropathy — the swollen muscles at the orbital apex squeezing the optic nerve. The warning signs are vision that is dropping, colours looking washed out or dimmer in one eye, and a new blind spot or field defect. The other sight-threatening presentation is corneal breakdown when the lids no longer close over an eye that has been pushed forward.
Both are managed urgently with high-dose intravenous glucocorticoids, and if optic-nerve function has not recovered within roughly two weeks, with urgent orbital decompression. That is a decision measured in days, taken by a doctor who can put hands and a slit lamp on you this week. No arrangement we could make abroad is faster or safer than the ophthalmology service nearest to you.
If any of that describes you, please seek urgent local assessment today. Come back to this page afterwards, when the question has changed from "how do I save this eye" to "what do I do about how it has left me".
The one question that decides everything: active or inactive?
Thyroid eye disease is not a steady state. It has a well-described natural trajectory: an inflammatory active phase lasting anywhere from about six months to five years — averaging roughly two years — followed by an inactive, fibrotic phase in which the inflammation burns out and the eyes stop changing. The disease does not return to baseline; what is left after the active phase is the mechanical and cosmetic residue, and that residue is what surgery addresses.
Clinicians grade activity with a seven-point clinical activity score covering pain on eye movement, spontaneous retrobulbar pain, redness and swelling of the lids and conjunctiva, and swelling of the caruncle. A score of 3 or more out of 7 is the conventional threshold for calling the disease active. Severity is a separate axis from activity — a burnt-out eye can be very proptotic and very misaligned while being completely inactive, and that patient is a surgical candidate while a mildly affected but inflamed patient is not.
| Phase | What is appropriate | Travelling for it? |
|---|---|---|
| Active, mild | Risk-factor control, lubricants, prisms for diplopia; selenium in selenium-deficient populations | No — nothing here needs a flight |
| Active, moderate-to-severe | Intravenous glucocorticoid protocol, IGF-1R antibody, mycophenolate, orbital radiotherapy, second-line biologics | Only if you can be present for the whole course and its monitoring |
| Active, sight-threatening | Urgent high-dose IV steroids; urgent decompression if the nerve does not recover | No — urgent local care |
| Inactive, stable ≥6 months | Staged rehabilitation: decompression, then strabismus surgery, then eyelid surgery | Yes — this is the phase where travel makes sense |
| Inactive but still changing month to month | Measurement and waiting | No — the target is still moving |
The practical instruction that follows is worth more than any quote on this page: bring two sets of measurements taken at different visits — exophthalmometry readings, an orthoptic assessment of your squint and lid position, and ideally the same imaging repeated. A single visit can describe your eyes. Only two can show whether they are still moving, and that is what decides whether a surgeon should be operating on you at all.
The drug that changed the arithmetic — and its five-month string attached
For seventy years thyroid eye disease had no targeted medical treatment. IGF-1R antibodies changed that, and for the first time gave a drug that reduces proptosis rather than only calming inflammation. The reason it matters to anyone reading a page about China is price. In the United States the originator product is published at approximately US$18,295 per 500 mg vial, with a full eight-dose course around US$146,000.
On 14 March 2025 China's National Medical Products Administration approved teprotumumab N01 (brand name Sycume, from Innovent Biologics) — China's first IGF-1R antibody and the second approved anywhere. Its launch list price was reported at about RMB 15,311 per vial; after national reimbursement negotiation, reported prices from early 2026 put it near RMB 5,966 per vial, a reduction of over 60%. The standard course is eight infusions three weeks apart — one vial for the first, two for each of the remaining seven — so fifteen vials in total.
| IGF-1R antibody course, drug cost only | Reported figure |
|---|---|
| US originator product, per 500 mg vial | ~US$18,295 |
| US originator product, full 8-dose course | ~US$146,000 |
| China, launch list price per vial (2025) | ~RMB 15,311 |
| China, post-negotiation price per vial (2026) | ~RMB 5,966 |
| China, 15-vial course at the negotiated price | ~RMB 89,000–95,000 |
| China, same course in US dollars (mid-2026 rates) | ~US$12,400–13,200 |
| Day-ward, infusion and monitoring across the course | $900–1,800 |
1. The reimbursement is not yours. The 60%–70% figures reported in Chinese coverage are what China's national medical insurance pays for its own enrollees. An overseas visitor pays the drug price, not the reimbursed share. The reason the number is still striking is the negotiated price itself, not the reimbursement.
2. The course cannot be compressed. Eight infusions three weeks apart is about twenty-one weeks from first dose to last. There is no version of this that fits in a two-week medical trip. It means either being in China for the treatment window, or accepting eight return journeys, and it means the audiometry and glucose monitoring have to keep working after you go home. If you cannot commit to finishing the course, a specialist should not start it.
3. Hearing. Otologic effects are a recognised feature of this drug class. A review of US adverse-event reports found otologic reactions in roughly 14% of teprotumumab reports; small prospective studies using formal audiometry found subjective symptoms in the majority of treated patients and measurable high-frequency audiometric change in most of one small cohort, which is why a baseline audiogram before the first infusion has become normal practice. Raised blood sugar is the other common effect and matters especially in diabetes. Ask who is doing your audiometry and when, before you ask what the drug costs.
One further honest note for readers whose home doctors will be managing them afterwards: the Chinese product is licensed by the NMPA, not by the FDA or EMA. It is the same target and the same drug class, but a physician at home may be unfamiliar with it and will want the infusion records, lot documentation and monitoring results. Collect those as you go rather than at the end.
The rest of the medical toolkit
The drug above is not the only option and is not first-line everywhere. European guidance for moderate-to-severe active disease has centred on an intravenous glucocorticoid protocol — a cumulative 4.5 g of methylprednisolone over twelve weeks (0.5 g weekly for six weeks, then 0.25 g weekly for six) combined with mycophenolate, with higher-dose schedules up to 7.5 g per cycle reserved for more severe presentations and an explicit ceiling of 8 g per treatment course because of the risk of severe liver injury at higher cumulative doses. That protocol is twelve weekly hospital visits, which raises exactly the same travel problem as the infusion course.
| Medical option | Typical role | China planning range |
|---|---|---|
| Selenium, 100 µg twice daily, 6 months | Mild, recent-onset disease in selenium-deficient populations | Nominal |
| IV methylprednisolone, 4.5 g / 12 weeks | First-line for moderate-to-severe active disease | $700–1,500 |
| Higher-dose IVMP cycle (up to 7.5 g) | Severe presentations, constant diplopia, marked proptosis | $900–1,900 |
| IGF-1R antibody, 8 infusions / 21 weeks | Proptosis and diplopia in active disease | ~$12,400–13,200 + monitoring |
| Orbital radiotherapy, fractionated course | Motility restriction and diplopia in active disease | $1,800–3,500 |
| Second-line biologics (e.g. tocilizumab, rituximab) | Steroid-resistant disease, specialist decision | Case by case |
| Specialist work-up: orbital CT/MRI, TRAb, fields, colour, Hertel | Before anything else | $350–800 |
Which of these is right for a given patient is a decision for an orbital specialist and an endocrinologist working together, on your imaging and your antibody levels. We can arrange the consultation; we cannot and do not choose the protocol, and no provider should be selling you one before they have seen your scans.
Surgery: the order is not negotiable
Once the disease is inactive and measurements have been stable, rehabilitation is done in a fixed sequence: orbital decompression → strabismus surgery → eyelid surgery. This is the one piece of thyroid eye disease care that facilitator pages consistently get wrong, usually by offering to fold the whole thing into one convenient trip.
The order exists because each step moves the target for the next. Decompression enlarges the bony socket and lets the globe settle back, which relieves the nerve and improves lid coverage — and it also, on average, worsens horizontal alignment, which is precisely why alignment is measured after decompression rather than before. Eyelid position depends in turn on where the globe and the eye finally sit, so lid work comes last. Surgeons typically leave three to six months between stages for measurements to settle. Combined single-session approaches do exist in the literature and can be appropriate in selected cases, but that is a specialist judgement about a particular patient — not a scheduling convenience, and not something to choose because it fits your annual leave.
| Stage | What it addresses | Wait before the next stage |
|---|---|---|
| 1. Orbital decompression | Proptosis, exposure, optic-nerve crowding | 3–6 months |
| 2. Strabismus surgery | Double vision from restricted, fibrotic muscles | 3–6 months |
| 3. Eyelid surgery | Lid retraction, exposure, appearance | Final stage |
Not everyone needs all three. Many inactive patients need only lid retraction repair; some need decompression alone. But if you need more than one, they happen in that order, and the honest consequence is that full rehabilitation is a nine-to-eighteen month project across two or three separate trips, not a package. Our strabismus surgery guide covers the alignment stage in detail, including the six-month stability gate that applies with particular force after thyroid eye disease, and our ptosis guide is worth reading for the distinction most patients need: thyroid disease usually causes the upper lid to sit too high (retraction), which is the opposite problem to a drooping lid and a different operation.
What it costs in China
Standard partner-hospital planning ranges, researched July 2026. These are not quotes; final pricing follows examination and imaging, and complexity varies widely in this condition.
| Procedure | China (planning range) | Published Western reference |
|---|---|---|
| Specialist work-up (orbital CT/MRI, bloods, fields, Hertel) | $350–800 | — |
| Fat-only / transconjunctival decompression, per orbit | $2,800–5,000 | US orbital decompression averaged ~$21,875 per encounter in a published analysis |
| Two-wall bony decompression, per orbit | $3,500–6,500 | |
| Three-wall decompression, per orbit | $5,000–8,500 | |
| Bilateral two-wall decompression | $6,500–11,000 | |
| Strabismus correction, one eye, 1–2 muscles | $1,400–2,400 | US private-pay commonly $5,000–9,600 |
| Strabismus, bilateral or 3–4 muscles | $2,200–3,600 | US private-pay commonly $6,000–12,000 |
| Upper-lid retraction repair, per lid | $1,200–2,400 | US oculoplastic lid procedures commonly $3,000–6,500 |
| Lower-lid retraction with spacer graft, per lid | $1,800–3,200 | |
| Upper-lid debulking as part of rehabilitation, both lids | $1,200–2,200 | — |
| IGF-1R antibody course (15 vials) + infusion & monitoring | ~$13,300–15,000 | ~US$146,000 drug list price for the course |
| IV methylprednisolone protocol, 4.5 g / 12 weeks | $700–1,500 | — |
The site's full eye surgery cost guide puts these alongside every other procedure, and the glaucoma and retina pricing page covers the other conditions where treatment is a course rather than an event.
How long you would actually be in China
| Pathway | Time required | Feasible as a trip? |
|---|---|---|
| IGF-1R antibody, 8 infusions | ~21 weeks, 8 visits | No — relocation or repeated travel |
| IV methylprednisolone, 4.5 g protocol | 12 weeks, weekly visits | No — same problem |
| Orbital radiotherapy course | ~2–3 weeks of daily fractions | Borderline — one long stay |
| Orbital decompression, one or both orbits | 10–14 days | Yes |
| Strabismus surgery (often adjustable suture) | 7–10 days | Yes |
| Eyelid retraction repair | 6–8 days | Yes |
| Full staged rehabilitation, all three stages | 9–18 months elapsed | Yes, as 2–3 separate trips |
Flight timing after orbital or lid surgery is a question of swelling and wound healing rather than the intraocular gas rules that apply after retinal work — our flying after eye surgery guide sets out the clearance windows procedure by procedure, and the surgeon's post-operative review, not the calendar, is what releases you.
Where the honest answer is "don't travel"
This is the section a facilitator would leave out, so it is the one worth reading twice.
- Your treatment is funded at home. In the United States the originator IGF-1R antibody is covered by many commercial plans and by Medicare Part B under prior authorisation; in countries with public health systems, moderate-to-severe thyroid eye disease is generally managed within specialist services. If your treatment is funded where you live, the price gap on this page is not a reason to fly, and the continuity is worth more across a condition measured in years. Confirm your position with your plan administrator or insurer — this is general information researched July 2026, not insurance advice.
- Your disease is still active. Rehabilitative surgery on a moving target is money spent on a result that will change. Wait, control the thyroid, stop smoking, and be re-measured.
- Anything is threatening your sight. Falling vision, dimmer or washed-out colour, a new field defect, or a cornea breaking down — be seen locally, urgently.
- You cannot complete the course. Twenty-one weeks of infusions or twelve weeks of steroid pulses started and abandoned is worse than not starting.
- You have nobody at home to follow you up. Audiometry, glucose, thyroid function, orthoptic measurements and long-term surveillance all continue after the trip ends. Arrange the ophthalmologist and endocrinologist who will hold your baseline before you travel, not after.
The things that cost nothing and matter more than the quote
- Stop smoking. It is the strongest modifiable factor in this disease — smokers get more severe eye involvement and respond less well to treatment. Nothing on this page will do as much for your eyes.
- Get the thyroid stable, in both directions. Swinging between over- and under-active is associated with worse eye disease; steady euthyroid function is part of the treatment.
- Ask about steroid cover before radioiodine. Radioiodine for Graves' disease is associated more often than surgery or antithyroid drugs with the eyes deteriorating afterwards in at-risk patients, and oral steroid prophylaxis is an established way to reduce that risk. This is a conversation with your endocrinologist before the treatment, not after.
- Selenium, in the right population. A randomised trial found that 100 µg twice daily for six months improved eye involvement and quality of life in mild, recent-onset disease, with the important caveat that the benefit is understood to apply where selenium intake is low.
- Protect the surface. Heavy lubrication, sleeping propped up, and taping the lids at night if they do not fully close. Unglamorous, and the difference between an irritated eye and an ulcerated one.
- Prisms before surgery. Stable double vision can often be managed optically while you wait out the active phase, which is preferable to operating early.
What to bring, and what to take home
Bring: two sets of exophthalmometry readings from different dates, orbital CT or MRI on disc rather than as a report, thyroid function and TRAb history, an orthoptic assessment of your deviation and lid measurements, a record of every steroid course you have had with cumulative doses, your smoking history stated honestly, and a baseline audiogram if you are considering the antibody. Take home: the operative note, the imaging, the drug lot and infusion records, the monitoring results, and the named contact details of the surgeon who treated you.
Our guide for foreign patients covers international departments, English-language records, payment and visas, and our safety assessment addresses the standards question directly. For where this work is concentrated, the best eye hospitals guide profiles the major institutions and their oculoplastic and orbital units, while the city comparison weighs access and flights — worth reading carefully here, because a staged rehabilitation means returning to the same team more than once.
Frequently asked questions
Is teprotumumab available in China, and what does it cost?
Yes. China's National Medical Products Administration licensed a domestically developed IGF-1R antibody, teprotumumab N01 (brand name Sycume, Innovent Biologics), for thyroid eye disease on 14 March 2025 — the first drug of this class approved in China and the second in the world. Its launch list price was reported at about RMB 15,311 per vial; following national reimbursement negotiation the price was reported to fall to about RMB 5,966 per vial from early 2026. The standard course is eight infusions three weeks apart, one vial for the first infusion and two for each of the remaining seven, so fifteen vials in total — roughly RMB 89,000–95,000 in drug cost, on the order of US$12,400–13,200 at mid-2026 exchange rates, plus day-ward, infusion and monitoring charges of about US$900–1,800. Published US figures for the originator product are approximately US$18,295 per 500 mg vial and about US$146,000 for a full course. Two honest caveats: China's reimbursement percentages apply to enrollees in the national medical insurance scheme, so an overseas visitor pays the drug price rather than the reimbursed share; and availability, prescription and monitoring are decisions for the treating hospital and specialist, not something a concierge can guarantee.
Can a course of teprotumumab be done in a single trip to China?
No, and this is the most important practical fact on the page. The standard schedule is eight infusions given three weeks apart, which spans about twenty-one weeks — close to five months — before the final dose. Nobody completes that as a two-week medical trip. Realistically it means either relocating to China for the treatment period, or a repeated-travel arrangement of eight return flights, and in either case a plan for baseline and follow-up audiometry and blood-glucose monitoring that continues after you go home. If you cannot commit to the whole schedule and its monitoring, this is not the treatment to travel for, and a specialist should not start a course you cannot finish.
When is it too early to have surgery for thyroid eye disease?
While the disease is still active. Thyroid eye disease follows a well-described trajectory — an inflammatory active phase lasting from about six months to five years, averaging around two years, followed by an inactive fibrotic phase in which the eyes stop changing. A clinical activity score of 3 or more out of 7 is the conventional threshold for calling the disease active. Rehabilitative surgery — decompression, strabismus correction, eyelid repositioning — is planned for the inactive phase, when measurements have been stable for a meaningful period, typically six months or more. Operating on an eye that is still moving means operating to a target that will have shifted by the time it heals. The exception is sight-threatening disease, which is treated urgently regardless of phase and which is a reason to be seen where you are, not to book a flight.
What is the correct order of thyroid eye disease surgery?
Orbital decompression first, then strabismus surgery, then eyelid surgery. The order is not a preference; each step changes the starting point for the next. Decompression moves the globe back into a larger socket and, on average, worsens horizontal alignment — which is precisely why alignment is measured after decompression rather than before. Eyelid position in turn depends on where the globe and the eyes finally sit, so lid work is last. Surgeons typically allow three to six months between stages for measurements to settle. A provider offering to compress the whole sequence into one convenient trip is offering an unpredictable result; combined single-session approaches exist in the literature but are a specialist judgement for selected cases, not a scheduling convenience.
How much does orbital decompression cost in China?
Standard partner-hospital planning ranges researched July 2026: fat-only or transconjunctival decompression US$2,800–5,000 per orbit, two-wall bony decompression US$3,500–6,500 per orbit, three-wall decompression US$5,000–8,500 per orbit, and bilateral two-wall decompression US$6,500–11,000. The imaging and specialist work-up that has to come first — orbital CT or MRI, thyroid antibodies and function, visual fields, colour vision and exophthalmometry — runs US$350–800. A published analysis of US costs put orbital decompression at an average of about US$21,875 per encounter. Final pricing follows examination and imaging, and whether decompression is appropriate at all is the operating surgeon's decision.
What are the risks of the IGF-1R antibody drugs?
Hearing is the one to understand before you consent. Otologic problems — hearing decline, tinnitus, aural fullness — are a recognised effect of this drug class. A review of US adverse-event reports found otologic reactions in about 14% of teprotumumab reports, while small prospective studies using formal audiometry found much higher rates of measurable change, including subjective symptoms in the majority of patients and high-frequency audiometric change in most of one small cohort. Practice has moved towards a baseline audiogram before the first infusion and monitoring during treatment. Raised blood sugar is the other common issue, which matters particularly if you are diabetic, along with infusion reactions, muscle cramps and hair thinning. None of that makes the drug a bad choice — for the right patient it can do what no other medical treatment for this condition does — but it does mean the monitoring plan is part of the treatment, not paperwork, and it has to work across the distance if you travel.
Which presentations of thyroid eye disease mean I should not travel?
Any suggestion of sight-threatening disease. Roughly 5 in 100 patients with thyroid eye disease develop compressive optic neuropathy, which is an emergency: falling vision, colours looking washed out or dimmer in one eye, a new visual-field defect. Corneal breakdown from lids that no longer close is the other sight-threatening presentation. Both are treated urgently with high-dose intravenous steroids and, if the optic nerve does not recover within about two weeks, urgent decompression. Those are days-and-weeks decisions made where you are, not a case for arranging international travel. The same applies while the disease is visibly worsening month to month — the useful thing then is control of the disease and of your thyroid, not a flight. Please have any of those symptoms assessed locally, today.
Should I travel for thyroid eye disease treatment at all?
Often not, and it is worth saying plainly. In the United States the originator IGF-1R antibody is covered by many commercial plans and by Medicare Part B under prior authorisation, and moderate-to-severe disease is generally managed within specialist services in countries with public systems — so a reader whose treatment is funded at home has little reason to fly, and the specialist relationship is worth more than the price difference across a condition measured in years. The cases where travel earns its place are narrower: uninsured or high-deductible patients facing a six-figure US drug price, patients whose plan has declined the drug, people who can actually be present in China for a treatment window, and inactive-phase patients wanting staged rehabilitative surgery at a fraction of Western private-pay cost. Check your own coverage before you price a trip — this is general information researched July 2026, not insurance advice, and your plan administrator or insurer is the only authority on your policy.
What can I do myself that changes the outcome?
More than the choice of hospital does. Stopping smoking is the single most important modifiable factor in thyroid eye disease — it worsens the disease and blunts the response to treatment. Getting and keeping thyroid function stable matters nearly as much, in both directions. If radioiodine is being considered for your Graves' disease and you already have eye involvement or risk factors, oral steroid prophylaxis is an established way to reduce the risk of the eyes deteriorating afterwards, and it is a conversation to have with your endocrinologist before treatment rather than after. In mild, recent-onset disease, selenium supplementation at 100 micrograms twice daily for six months improved eye involvement and quality of life in a randomised trial, with the caveat that the benefit is understood to apply in selenium-deficient populations. Sleeping propped up, lubricating heavily and taping the lids at night if they do not close are unglamorous and genuinely protective.